| 1. |
- Khatri, C, et al.
(författare)
-
Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study
- 2021
-
Ingår i: BMJ open. - : BMJ. - 2044-6055. ; 11:11, s. e050830-
-
Tidskriftsartikel (refereegranskat)abstract
- Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.SettingProspective, international, multicentre, observational cohort study.ParticipantsPatients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative).Primary outcome30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality.ResultsThis study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p<0.001), age >80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.6 (0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787).ConclusionsPatients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups.Trial registration numberNCT04323644
|
|
| 2. |
|
|
| 3. |
- Alffenaar, J. W. C., et al.
(författare)
-
Clinical standards for the dosing and management of TB drugs
- 2022
-
Ingår i: The International Journal of Tuberculosis and Lung Disease. - Paris, France : International Union Against Tuberculosis and Lung Disease. - 1027-3719 .- 1815-7920. ; 26:6, s. 483-
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Background: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice' for dosing and management of TB drugs.Methods: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.Results: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.Conclusion: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.
|
|
| 4. |
- Singh, K. P., et al.
(författare)
-
Clinical standards for the management of adverse effects during treatment for TB
- 2023
-
Ingår i: The International Journal of Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1027-3719 .- 1815-7920. ; 27:7, s. 506-519
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitiv-ity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person -centred, consensus-based approach to minimise the impact of AE TB treatment.
|
|
| 5. |
- du Cros, P, et al.
(författare)
-
Standards for clinical trials for treating TB
- 2023
-
Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - 1815-7920. ; 27:12, s. 885-898
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
- van Velden, J. L., et al.
(författare)
-
Futures for invasive alien species management : using bottom-up innovations to envision positive systemic change
- 2023
-
Ingår i: Sustainability Science. - 1862-4065 .- 1862-4057. ; 18:6, s. 2567-2587
-
Tidskriftsartikel (refereegranskat)abstract
- Invasive alien species (IAS) pose a key threat to biodiversity, the economy and human well-being, and continue to increase in abundance and impact worldwide. Legislation and policy currently dominate the global agenda for IAS, although translation to localised success may be limited. This calls for a wider range of responses to transform IAS management. An under-appreciated strategy to achieve success may come from bottom-up, experimental innovations (so-called “seeds”), which offer alternative visions of what may be possible for IAS management in the future. We present an application of a participatory process that builds on such innovations to create alternative visions of the future, with actionable pathways to guide change. Through a series of workshops with practitioners and academics, we used this process to explore alternative positive futures for IAS management in South Africa. We then identified a set of domains of change, that could enable these visions to be actioned by appropriate stakeholders. The domains of change highlight the social–ecological nature of the IAS sector, with interconnected actions needed in financial, cultural, social, technological and governance spheres. Key domains identified were the need to shift mindsets and values of society regarding IAS, as well as the need for appropriate and functional financing. This participatory futuring process offers a way to interrogate and scale bottom-up innovations, thereby creating optimism and allowing stakeholders to engage constructively with the future. This represents an important step in fostering the potential of bottom-up innovations to transform IAS management.
|
|
| 7. |
- Gafar, Fajri, et al.
(författare)
-
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents : a systematic review and individual patient data meta-analysis
- 2023
-
Ingår i: European Respiratory Journal. - : European Respiratory Society. - 0903-1936 .- 1399-3003. ; 61:3
-
Forskningsöversikt (refereegranskat)abstract
- Background Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level.Methods We systematically searched MEDLINE, Embase and Web of Science (1990–2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration–time curve from 0 to 24 h post-dose (AUC0–24) and peak plasma concentration (Cmax) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC0–24 and Cmax were assessed with linear mixed-effects models.Results Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC0–24 were summarised for isoniazid (18.7 (95% CI 15.5–22.6) h·mg·L−1), rifampicin (34.4 (95% CI 29.4–40.3) h·mg·L−1), pyrazinamide (375.0 (95% CI 339.9–413.7) h·mg·L−1) and ethambutol (8.0 (95% CI 6.4–10.0) h·mg·L−1). Our multivariate models indicated that younger age (especially <2 years) and HIV-positive status were associated with lower AUC0–24 for all first-line anti-TB drugs, while severe malnutrition was associated with lower AUC0–24 for isoniazid and pyrazinamide. N-acetyltransferase 2 rapid acetylators had lower isoniazid AUC0–24 and slow acetylators had higher isoniazid AUC0–24 than intermediate acetylators. Determinants of Cmax were generally similar to those for AUC0–24.Conclusions This study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring.
|
|
| 8. |
- Marais, Heidi L., 1996-, et al.
(författare)
-
Outlining Process Monitoring and Fault Detection in a Wastewater Treatment and Reuse System
- 2020
-
Ingår i: European Control Conference 2020, ECC 2020. - : Institute of Electrical and Electronics Engineers Inc.. - 9783907144015 ; , s. 558-563
-
Konferensbidrag (refereegranskat)abstract
- Process control is an important part of any industrial system. In a wastewater reuse system this remains true. Process monitoring and fault detection (FD) are important to ensure that the control system has access to reliable data which can be used in making decisions about the operation of the process. The reuse scenario being considered in this work is that of utilizing the nutrients from the wastewater as fertilizer to agricultural soil along with using the water for irrigation purposes. This paper identifies variables that are important to the control of the process and should be a focus of monitoring and FD. In wastewater treatment these variables include temperatures, pressures, liquid levels, flow rates, pH, conductivity, biomass content, suspended solids concentration, dissolved oxygen content, total organic carbon, and the concentrations of nitrate and ammonium. The variables of interest in the reuse of nutrients and water for agriculture include soil moisture, ambient conditions, plant height, biomass content, photosynthetic activity of the crop, leaf area and leaf water content, as well as the concentrations of several ions both in the soil and in the plant. Challenges associated with process monitoring and FD specific to the two processes are also discussed, examples of these are the high dimensionality of the problem, the harsh conditions that sensors must operate in and the non-linear relationships between variables. This information will be used in future work when comparing specific FD methods to ensure that methods chosen are capable of overcoming the commonly encountered problems.
|
|
| 9. |
|
|
